Global Next Generation Antibody Therapeutics Market Strategic Research Report

Scope of the Report

The global Next Generation Antibody Therapeutics market size is predicted to grow from US$ 17,760 million in 2025 to US$ 61,130 million in 2032; it is expected to grow at a CAGR of 19.5% from 2026 to 2032.

Building on the huge success of monoclonal antibody therapeutics, the next generation of antibody-based products such as Antibody Drug Conjugate (ADC) and Bispecific Antibody (BsAb) is now opening up new opportunities.

The global next-generation antibody therapeutics market is expected to grow significantly over the next decade, driven by the increasing prevalence of cancer, autoimmune diseases, and infectious diseases, along with advancements in biotechnology. Oncology will remain the largest segment, but there will be strong growth in autoimmune diseases, infectious diseases, and neurological conditions.

In conclusion, technological advancements, regulatory support, and the increasing use of antibodies in combination therapies will continue to fuel the market's growth, making next-gen antibody therapeutics one of the most promising areas in biopharmaceutical innovation.Global key players of next generation antibody therapeutics include Roche, Seagen, Amgen, Pfizer, Takeda, etc. The top two players hold a share over 70%. North America is the largest market, has a share about 65%, followed by Europe and Asia-Pacific, with share 16% and 15%, separately. In terms of product type, Antibody Drug Conjugate (ADC) is the largest segment, occupied for a share of 60%, and in terms of application, Cancer has a share about 66 %.

This report presents a comprehensive overview of the global Next Generation Antibody Therapeutics market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Antibody Drug Conjugate (ADC)
• Bispecific Antibody (BsAb)

Segment by players, this report covers

• Roche
• Amgen
• Pfizer
• Takeda
• Daiichi Sankyo
• Seagen
• Astellas
• Immunomedics
• GSK
• Immunocore
• ADC Therapeutics

Segment by Application

• Cancer
• Haemophilia
• Other Non-Cancer Diseases

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Next Generation Antibody Therapeutics market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Cancer, Haemophilia, Other Non-Cancer Diseases evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact